Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-22
2007-05-22
Jones, Dameron L. (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S358000, C544S359000, C544S336000, C424S001650, C424S001110
Reexamination Certificate
active
10852611
ABSTRACT:
Substituted pyrido[1,2-a]pyrazines of general formula I; wherein Ar and Ar1represent various carbocyclic and heterocyclic aromatic rings; A represents O, S, SO, SO2, CHOH, C═O, or —(CR3R4); and n is 0–2, as well as precursors thereto, are ligands for dopamine receptor subtypes and serotonin (5HT) within the body and are therefore useful in the treatment of disorders of the dopamine and serotonin systems:
REFERENCES:
patent: 5122525 (1992-06-01), Bright et al.
patent: 5602128 (1997-02-01), Baudy et al.
patent: 5741789 (1998-04-01), Hibschman et al.
patent: 5852031 (1998-12-01), Desai et al.
patent: 6231833 (2001-05-01), Desai et al.
patent: 512755 (1992-11-01), None
patent: 759299 (1997-02-01), None
patent: 216637 (1998-06-01), None
patent: WO 90/08144 (1990-07-01), None
patent: WO 90/08148 (1990-07-01), None
patent: WO 92/00074 (1992-01-01), None
patent: WO 96/23789 (1996-08-01), None
patent: WO 97/03068 (1997-01-01), None
patent: WO 97/08159 (1997-03-01), None
patent: WO 97/17343 (1997-05-01), None
patent: WO 99/52901 (1999-10-01), None
patent: WO 99/52907 (1999-10-01), None
Reitz, Allen, et al., Orally Active Benzamidse Antipsychotic Agents with Affinity for Dopamine D2, Serotonin 5-HT1A, and Adrenergic α1Receptors,Journal of Medicinal Chemistry, 41(12): 1997-2009, 1998.
Taverne, Thierry, et al. “Novel Benzothiazolin-2-one and Benzoxazin-3-one Arylpiperazine Derivatives with Mixed 5HT1A/D2Affinity as Potential Atypical Antipsychotics”,J. Med. Chem., 41: 2010-2018 (1998).
De Vry, Jean, et al. “Characterization of the Aminomethylchrma Derviative BAY X 3702 as a Highly Potent 5-Hydroxytryptamine1AReceptor Antagonist”,J. Pharm. and Experim. Therap., 284(3): 1082-1094 (1998).
Sanner, Mark A., “Selective dopamine D4receptor antagonists”Exp. Opin. Ther. Patents1998, 8(4), pp. 383-393.
Robertson, D.W. “Recent progress in serotonin (5-HT)1A receptor modulators”,Ann. Rep. Med. Chem., 1995 30, pp. 1-9.
Wolff, M.C. et al., “Pharmacological profile of LY301317, a potent and selective 5-HT1a agonist”,Drug Dev. Res.1997, 40, pp. 17-34.
MKC-242,Drugs of the Future, 1997, 22, pp. 225-228.
Sharma, R. P. Shapiro, L.E., “The 5HT1a receptor system: possible implication for schizophrenic negative symptomatology”Psych. Ann.1996, 26 pp. 88-92.
Wadenberg, M.L. “Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat”,Neurosci. Biobehav. Rev., 1996, 20 pp. 325-339.
Artigas, R. et al., “Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1a antagonists”,Trends Neurosci., 1996, 19, pp. 378-383.
Shiue, C. Y. et al., “p-[18F]-MPPF: a potential radioligand for PET studies of 5-HT1a receptors in humans”,Synapse, 1997, 25, pp. 147-154.
Ramage, A.G. and Fozard, John R., “Exidence that the putative 5-HT1a receptor agonists, 8-OH-DPAT and ipsapirone, have a central hypotensive action that differs from that of clonidine in anesthetized cats”,Eur. J. Pharmacol., 1987, 138, pp. 179-191.
DeVry, J., “5HT1a receptor agonists: recent developments and controversial issues”,Psychopharmacol., 1995, 12, 121, pp. 1-26.
McCall, R.B., Clement, M.E. “Role of serotonin 1A and serotonin 2 receptors in the central regulation of the cardiovascular system”,Pharmacol. Rev., 1994, 46, pp. 231-243.
Neal-Beliveau, et al., “Serotonergic involvement in haloperidol induced catalepsy”,J. Pharmacol. Exp. Ther., 1993, 265,pp. 207-217.
Izquierdo, et al. “Memory Formation: The Sequence of Biochemical Events in the Hippocampus and Its Connection to Activity in Other Brain Structures”,Neurobiology, 68:285-316 (1997).
Desai Kishor A.
Fliri Anton F.
Sanner Mark A.
Ashbrook Charles W.
Cohen Mark J.
Goodman Rosanne
Jones Dameron L.
Pfizer Inc.
LandOfFree
2,7-substituted octahydro-1H-pyrido[1,2-a]pyrazine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2,7-substituted octahydro-1H-pyrido[1,2-a]pyrazine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2,7-substituted octahydro-1H-pyrido[1,2-a]pyrazine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3751747